Atlas FDA

ADVIA Centaur Anti-HBe2 (aHBe2) assay

FDA premarket approval P200017 · decided 2021-07-14

Approval details

PMA number
P200017
Trade name
ADVIA Centaur Anti-HBe2 (aHBe2) assay
Generic name
Qualitative and Quantitative Hepatitis B Virus Antibody assays
Applicant
Siemens Healthcare Diagnostics, Inc.
Date received
2020-03-09
Decision date
2021-07-14
Days to decision
492 days
Decision code
APRL
Product code
SEI
Advisory committee
Microbiology
Expedited review
No
Location
Tarrytown, NY
Statement
Approval of the ADIVA Centaur Anti-HBe2 (aHBe2) assay. The qualitative detection of antibodies to the e antigen of the hepatitis B virus (HBV) in human pediatric (2–21 years old) and adult serum, EDTA plasma, or lithium heparin plasma using the ADVIA Centaur systems (XP/XPT/CP). Assay results, in conjunction with other laboratory results and clinical information may be used as an aid in the diagnosis of hepatitis B virus (HBV) infection in patients with signs or symptoms of hepatitis B infection

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
Atellica CH Acetaminophen 2 (ACTM) (K261364)Siemens Healthcare Diagnostics, Inc.2026-07-24
Atellica CH Diazo Total Bilirubin (D_TBil) (K251998)Siemens Healthcare Diagnostics, Inc.2026-02-27
Atellica® IM TSH3-Ultra II (TSH3ULII) (K251543)Siemens Healthcare Diagnostics, Inc.2026-02-06
Atellica IM Total PSA II (tPSAII) (K251630)Siemens Healthcare Diagnostics, Inc.2026-01-05
ADVIA Centaur Anti-Thyroglobulin II (aTgII) (K250816)Siemens Healthcare Diagnostics, Inc.2025-12-04
ADVIA Centaur Anti-Thyroid Peroxidase II (K250250)Siemens Healthcare Diagnostics, Inc.2025-10-17
Atellica IM Thyroglobulin (Tg) (K242981)Siemens Healthcare Diagnostics, Inc.2025-06-20
Atellica® CH Creatinine_3 (Crea3) (K242685)Siemens Healthcare Diagnostics, Inc.2024-12-04